Darunavir 600mgTablet
HIV / Antiretroviral

Darunavir 600mg

Darunavir Ethanolate

Second-generation HIV protease inhibitor with high genetic barrier to resistance, recommended as preferred PI for second-line ART. Manufactured by Hetero and Cipla for HIV program export.

Strengths

400mg / 600mg / 800mg

Packing

60 tablets/bottle

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request QuotationWhatsApp
Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Darunavir Ethanolate equivalent to Darunavir 400mg / 600mg / 800mg
Dosage Form
Tablet
Available Strengths
400mg / 600mg / 800mg
Packing
60 tablets/bottle
Route of Administration
Oral, with food (must be boosted with ritonavir or cobicistat)
Dosage
Treatment-naive: 800mg + ritonavir 100mg once daily; Treatment-experienced: 600mg + ritonavir 100mg twice daily
Indications
HIV-1 infection in combination with ritonavir or cobicistat and other antiretrovirals
Country of Origin
India (WHO-GMP Certified)
Storage
Store at 25°C
Shelf Life
36 months
Side Effects
Diarrhea, nausea, rash, headache, abdominal pain, elevated transaminases, hyperlipidemia
Precautions
Must be co-administered with ritonavir or cobicistat; sulfonamide cross-allergy possible; hepatotoxicity risk; rash can be severe; extensive drug interactions via CYP3A4

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Efavirenz 600mgTablet

Efavirenz 600mg

Efavirenz

Second-generation NNRTI that allosterically inhibits HIV-1 reverse transcriptase, a backbone of PEPFAR-supported first-line HIV treatment in sub-Saharan Africa and Southeast Asia. Available in the landmark fixed-dose combination TDF/3TC/EFV (Atripla/generic), which transformed HIV care globally with a once-daily single-pill regimen.

50mg / 200mg / 600mg
Lopinavir + Ritonavir 200/50mgTablet

Lopinavir + Ritonavir 200/50mg

Lopinavir + Ritonavir

Fixed-dose combination where sub-therapeutic ritonavir inhibits CYP3A4 to dramatically boost lopinavir plasma levels, achieving reliable viral suppression without food restrictions for the tablet formulation. Widely used in pediatric HIV as oral solution and an affordable PEPFAR-supported generic in resource-limited settings globally.

200mg + 50mg (tablet); 80mg + 20mg/mL (solution)
Atazanavir + Ritonavir 300/100mgCapsule

Atazanavir + Ritonavir 300/100mg

Atazanavir + Ritonavir

Ritonavir-boosted azapeptide protease inhibitor distinguished by its unique pharmacokinetic characteristic of causing benign indirect hyperbilirubinemia (marker of absorption), once-daily dosing convenience, and a significantly more favorable lipid profile than lopinavir/ritonavir. Preferred second-line choice in resource-limited settings and in patients with dyslipidemia or cardiovascular risk.

150mg / 200mg / 300mg (atazanavir); 100mg (ritonavir)

Need bulk pricing for Darunavir 600mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote